Jupiter Topco LLC Makes New Investment in 4D Molecular Therapeutics, Inc. $FDMT

Jupiter Topco LLC bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the second quarter, Holdings Channel.com reports. The fund bought 5,746,289 shares of the company’s stock, valued at approximately $76,466,000. Jupiter Topco LLC owned approximately 0.11% of 4D Molecular Therapeutics at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of 4D Molecular Therapeutics in the second quarter worth about $59,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter valued at about $41,000. Daiwa Securities Group Inc. raised its holdings in 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares during the last quarter. Susquehanna Portfolio Strategies LLC acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $77,000. Finally, Martingale Asset Management L P lifted its stake in 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after purchasing an additional 1,303 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

FDMT has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. The Goldman Sachs Group reiterated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.62.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $14.91 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The company has a market capitalization of $823.63 million, a PE ratio of -5.67 and a beta of 2.73. The firm’s 50-day moving average is $12.11 and its two-hundred day moving average is $10.30. 4D Molecular Therapeutics, Inc. has a 12 month low of $5.97 and a 12 month high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Insider Buying and Selling

In related news, insider David Kirn sold 114,746 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. This represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 200,496 shares of company stock worth $2,240,244 over the last quarter. 7.90% of the stock is currently owned by insiders.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.